Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.
FDA Cracks Down on Telehealth Claims for Compounded Weight-Loss Drugs
The US FDA sent 25 warning letters to telehealth companies over unsubstantiated claims about compounded semaglutide and other weight-loss drugs. This action highlights regulatory scrutiny in the peptide and GLP-1 space, with implications for researchers and industry professionals.
US warns GLP-1 copycat makers over misleading claims
The United States has issued a warning to manufacturers of GLP-1 copycat drugs, cracking down on misleading claims about these products. The action targets makers who are reportedly marketing unauthorized versions of popular GLP-1 medications, which are used for diabetes and weight loss. The warning emphasizes that such claims could mislead consumers and violate regulations.